Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2000248 Feb 2020

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2000003 Jan 2020

INTENDED FOR UK HEALTHCARE PROFESSIONALS
Trimbow® Logo - beclometasone/formoterol/glycopyrronium (87/5/9 mcg) Extrafine formulation
Background

Think triple (ICS/LABA/LAMA),
think Trimbow

trimbow_subheader-mobile

The only extrafine formulation ICS/LABA/LAMA

combination1,2

Designed to reach the large and small airways1,3


Trimbow pMDI 87/5/9 is indicated for the maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.1

Trimbow® Device

Each dose contains three compounds for the treatment of asthma:1

  • Beclometasone
  • Formoterol
  • Glycopyrronium

Trimbow – now licensed for adult asthma patients uncontrolled on medium dose ICS/LABA who have experienced an exacerbation in the previous year1

Extrafine formulation like Fostair® (beclometasone/formoterol)1,4

Familiar pMDI device, b.d. dosing and licensed for use with an AeroChamber Plus® spacer1,5,6

Reduction in moderate and severe exacerbations vs. medium dose ICS/LABA (Fostair pMDI 100/6)1,7

To request a visit from a Chiesi representative to learn more about Trimbow, please click here.

For additional information to share with your patients who have been prescribed Trimbow, please visit our Trimbow patient and carer site.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.